Welichem Biotech Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 4

Employees

  • Latest Deal Type
  • M&A

Welichem Biotech General Information

Description

Developer of therapeutic drugs intended for autoimmune diseases. The company is engaged in the discovery and development of small molecule therapeutics, thereby enabling its clients to be provided with quality products at a competitive price.

Contact Information

Formerly Known As
Welichem Technology
Ownership Status
Acquired/Merged
Financing Status
Formerly Angel backed
Corporate Office
  • 4475 Wayburne Drive
  • Suite 316
  • Burnaby, British Columbia V5G 3L1
  • Canada
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Acquirer
LJ Resources
Vertical(s)
Corporate Office
  • 4475 Wayburne Drive
  • Suite 316
  • Burnaby, British Columbia V5G 3L1
  • Canada

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Welichem Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 22-Jul-2014 Completed Generating Revenue
2. IPO 25-May-2005 Completed Generating Revenue
1. Angel (individual) 01-May-2005 $1.9M $1.9M Completed Generating Revenue
To view Welichem Biotech’s complete valuation and funding history, request access »

Welichem Biotech Patents

Welichem Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2628459-T3 Novel sulfonamide compounds for growth inhibition of metastatic tumors Active 09-Jul-2010
JP-5918227-B2 Novel sulfonamide compounds for inhibiting the growth of metastatic tumors Active 09-Jul-2010
CA-2841217-A1 Novel sulfonamide compounds for inhibition of metastatic tumor growth Active 09-Jul-2010
CA-2841217-C Novel sulfonamide compounds for inhibition of metastatic tumor growth Active 09-Jul-2010
EP-2590938-A1 Novel sulfonamide compounds for inhibition of metastatic tumor growth Active 09-Jul-2010 A61K31/63
To view Welichem Biotech’s complete patent history, request access »

Welichem Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Welichem Biotech Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
MedInnova Partners Venture Capital Minority
WUTIF Capital Angel Group Minority
To view Welichem Biotech’s complete investors history, request access »

Welichem Biotech FAQs

  • When was Welichem Biotech founded?

    Welichem Biotech was founded in 1995.

  • Where is Welichem Biotech headquartered?

    Welichem Biotech is headquartered in Burnaby, Canada.

  • What is the size of Welichem Biotech?

    Welichem Biotech has 4 total employees.

  • What industry is Welichem Biotech in?

    Welichem Biotech’s primary industry is Pharmaceuticals.

  • Is Welichem Biotech a private or public company?

    Welichem Biotech is a Private company.

  • What is Welichem Biotech’s current revenue?

    The current revenue for Welichem Biotech is .

  • How much funding has Welichem Biotech raised over time?

    Welichem Biotech has raised $1.9M.

  • Who are Welichem Biotech’s investors?

    MedInnova Partners and WUTIF Capital have invested in Welichem Biotech.

  • When was Welichem Biotech acquired?

    Welichem Biotech was acquired on 22-Jul-2014.

  • Who acquired Welichem Biotech?

    Welichem Biotech was acquired by LJ Resources.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process